Abstract
To investigate the clinical effect of riboflavin sodium phosphate on prevention of radiotherapy related esophagitis (RRE). This retrospective study involved 55 patients with middle and advanced esophageal cancer who were divided into an experimental group of 28 and a control group of 27 patients. Those in the experimental group were treated with riboflavin sodium phosphate combined with conventional symptomatic treatment during radiotherapy; while patients in control group received the latter alone. The incidence and degree of RRE were compared after radiotherapy. The incidences of RRE in experimental and control group were 53.5% and 81.4%, respectively (p<0.05); the incidence of stages III and IV RRE in the experimental group was 17.8%, while in the control group it was 44.4% (p<0.05). Riboflavin sodium phosphate could significantly prevent RRE and reduce the incidence of stage III and IV disease. These results were worthy of further confirmation by randomized controlled trials.
Highlights
Materials and MethodsEsophageal cancer is a common malignant tumor in China, according to a report from World Health Organization, about 50% of esophageal cancer occurred in China
Choy reported that compared with radiotherapy alone, concurrent chemo(chemotherapy consisted with carboplatin and paclitaxel) and radiotherapy could significantly reduce the tolerance of esophagus, and is associated with an occurrence of acute esophagitis at an incidence as high as 46% (Choy et al, 2005)
Fifty five patients with middle and advanced esophageal cancer treated in our department from June 2013 to December 2013 were enrolled and divided into experimental group with 28 and control group with 27 patients
Summary
Esophageal cancer is a common malignant tumor in China, according to a report from World Health Organization, about 50% of esophageal cancer occurred in China. Radiotherapy is a standard treatment for middle and advanced radioactive esophageal cancer that can not be cured with surgery. Radiotherapy related esophagitis (RRE), one of the most common complications in the process of esophageal cancer treatment with an incidence of about 85%, is a main symptom for patients in this cohort. Prevention and treatment of RRE should be carefully considered in the process of radiotherapy for patients with esophageal cancer. This retrospective study enrolled patients with middle and advanced esophageal cancer in 2013. We hypothesized that riboflavin sodium phosphate by intravenous infusion could prevent and treat patients with RRE
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Pacific journal of cancer prevention : APJCP
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
